Literature DB >> 11553032

Role of angiotensin type 2 receptors in human forearm vascular responses of normal volunteers.

S Phoon1, L G Howes.   

Abstract

1. It has been hypothesized that the expression of angiotensin (Ang) II type 2 (AT(2)) receptors may become important in vascular disease; however, the functional existence of AT(2) receptors in normal adult humans remains to be established. 2. Vascular responses to AngII after the administration of the specific AT(2) receptor antagonist PD 123319 were determined in the forearm circulation of normal volunteers. 3. PD 123319 (8 microg/min) did not alter basal forearm blood flow, or forearm blood flow or forearm vascular resistance responses to AngII. 4. These results suggest that AT(2) receptors do not play a significant role in the regulation of forearm blood flow or forearm vascular resistance of normal volunteers, but do not preclude a role for AT(2) receptors in other vascular beds or in patients with cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553032     DOI: 10.1046/j.1440-1681.2001.03511.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  4 in total

Review 1.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

2.  AT(2) receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions.

Authors:  Jun Katada; Masataka Majima
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 3.  Vascular angiotensin II actions mediated by angiotensin II type 2 receptors.

Authors:  Ruth E Hannan; Robert E Widdop
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

Review 4.  AT2 receptors: functional relevance in cardiovascular disease.

Authors:  Emma S Jones; Antony Vinh; Claudia A McCarthy; Tracey A Gaspari; Robert E Widdop
Journal:  Pharmacol Ther       Date:  2008-08-31       Impact factor: 12.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.